|
||
|
SGLT2 inhibitors in patients with cardiovascular or chronic kidney disease or heart failure (n = 300). |
|
||||||||
| Part of: Siderova M, Shopov G, Kehayova G, Dragomanova S (2025) Organ-protective antidiabetic prescriptions in type 2 diabetes – a single institution experience. Pharmacia 72: 1-7. https://doi.org/10.3897/pharmacia.72.e163319 |